NL1004643A1 - Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen. - Google Patents

Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen.

Info

Publication number
NL1004643A1
NL1004643A1 NL1004643A NL1004643A NL1004643A1 NL 1004643 A1 NL1004643 A1 NL 1004643A1 NL 1004643 A NL1004643 A NL 1004643A NL 1004643 A NL1004643 A NL 1004643A NL 1004643 A1 NL1004643 A1 NL 1004643A1
Authority
NL
Netherlands
Prior art keywords
crystals
protamine
pharmaceutical formulations
human insulin
containing pharmaceutical
Prior art date
Application number
NL1004643A
Other languages
English (en)
Other versions
NL1004643C2 (nl
Inventor
Michael Rosario De Felippis
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL1004643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NL1004643A1 publication Critical patent/NL1004643A1/nl
Application granted granted Critical
Publication of NL1004643C2 publication Critical patent/NL1004643C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL1004643A 1994-06-16 1996-11-29 Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen. NL1004643C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26063394 1994-06-16
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (2)

Publication Number Publication Date
NL1004643A1 true NL1004643A1 (nl) 1996-12-17
NL1004643C2 NL1004643C2 (nl) 1997-02-12

Family

ID=22989963

Family Applications (2)

Application Number Title Priority Date Filing Date
NL1000565A NL1000565C2 (nl) 1994-06-16 1995-06-14 Complex van een insuline-analoog en protamine, dit complex bevattende farmaceutische formuleringen en bereidingswerkwijzen daarvan.
NL1004643A NL1004643C2 (nl) 1994-06-16 1996-11-29 Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL1000565A NL1000565C2 (nl) 1994-06-16 1995-06-14 Complex van een insuline-analoog en protamine, dit complex bevattende farmaceutische formuleringen en bereidingswerkwijzen daarvan.

Country Status (37)

Country Link
US (3) US5461031A (nl)
JP (1) JP3812962B2 (nl)
KR (1) KR100386038B1 (nl)
CN (1) CN1145641C (nl)
AT (1) AT408611B (nl)
BE (1) BE1009409A5 (nl)
BR (1) BR9502797A (nl)
CA (1) CA2151564C (nl)
CH (2) CH693019A5 (nl)
CO (1) CO4410204A1 (nl)
CZ (1) CZ294556B6 (nl)
DE (1) DE19521753B4 (nl)
DK (1) DK176213B1 (nl)
ES (1) ES2091728B1 (nl)
FI (1) FI118208B (nl)
FR (1) FR2721215B1 (nl)
GB (1) GB2290294B (nl)
GR (1) GR1002494B (nl)
HU (1) HU218943B (nl)
IE (1) IE68852B1 (nl)
IL (1) IL114153A (nl)
IT (1) IT1276722B1 (nl)
LU (1) LU88627A1 (nl)
MY (1) MY116831A (nl)
NL (2) NL1000565C2 (nl)
NO (1) NO320808B1 (nl)
NZ (1) NZ272360A (nl)
PE (1) PE34496A1 (nl)
PL (1) PL183284B1 (nl)
PT (1) PT101723B (nl)
RO (1) RO115124B1 (nl)
SE (1) SE509295C2 (nl)
SI (1) SI9500199A (nl)
TW (1) TW347334B (nl)
UA (1) UA34468C2 (nl)
YU (1) YU39795A (nl)
ZA (1) ZA954941B (nl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
WO1997048414A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S INSULIN PREPARATIONS CONTAINING NaCl
DE69829953T2 (de) * 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
EP1283051B1 (en) * 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010007853A1 (en) * 1998-01-08 2001-07-12 Dimarchi Richard Dennis Method for administering monomeric insulin analogs
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
BR0207422A (pt) * 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
CN1635900A (zh) * 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CA2463803A1 (en) * 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20120225033A1 (en) * 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
MXPA05013723A (es) 2003-06-17 2006-03-13 Sembiosys Genetics Inc Metodos para loa produccion de insulina en plantas.
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
ATE433746T1 (de) * 2004-03-12 2009-07-15 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005291233B2 (en) * 2004-10-05 2011-02-03 Novo Nordisk A/S A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088294A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugate based systems for controlled drug delivery
US20110293562A1 (en) 2009-02-12 2011-12-01 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
RU2016132386A (ru) * 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
BR112016016290A2 (pt) 2014-01-13 2017-10-03 Thermalin Diabetes Llc Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US20230134116A1 (en) 2020-03-31 2023-05-04 Protomer Technologies, Inc. Conjugates for selective responsiveness to vicinal diols
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE10075034I1 (de) * 1987-02-25 2001-05-23 Novo Nordisk As Insulinderivate
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
AU6995794A (en) * 1993-06-21 1995-01-17 Novo Nordisk A/S Aspb28 insulin crystals
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations

Also Published As

Publication number Publication date
NZ272360A (en) 1997-02-24
IL114153A (en) 2000-09-28
HU218943B (hu) 2001-01-29
IE68852B1 (en) 1996-07-24
DK176213B1 (da) 2007-02-12
ATA101795A (de) 2001-06-15
ES2091728B1 (es) 1998-02-01
BE1009409A5 (fr) 1997-03-04
ZA954941B (en) 1996-12-17
US5461031A (en) 1995-10-24
NL1000565A1 (nl) 1995-12-18
ITMI951277A1 (it) 1996-12-14
NL1000565C2 (nl) 1996-12-03
FR2721215B1 (fr) 1997-08-14
CN1145641C (zh) 2004-04-14
NO952356D0 (no) 1995-06-14
CH693019A5 (de) 2003-01-31
IE950435A1 (en) 1995-12-27
IL114153A0 (en) 1995-10-31
NO320808B1 (no) 2006-01-30
TW347334B (en) 1998-12-11
ITMI951277A0 (it) 1995-06-14
MY116831A (en) 2004-04-30
CA2151564C (en) 2003-02-11
PL309100A1 (en) 1995-12-27
CZ294556B6 (cs) 2005-02-16
ES2091728A1 (es) 1996-11-01
CH689934A5 (de) 2000-02-15
GB2290294A (en) 1995-12-20
JP3812962B2 (ja) 2006-08-23
FI118208B (fi) 2007-08-31
DE19521753A1 (de) 1995-12-21
KR100386038B1 (ko) 2003-08-27
HUT71908A (en) 1996-02-28
NO952356L (no) 1995-12-18
FR2721215A1 (fr) 1995-12-22
UA34468C2 (uk) 2001-03-15
LU88627A1 (fr) 1996-02-01
HU9501717D0 (en) 1995-08-28
IT1276722B1 (it) 1997-11-03
FI952932A0 (fi) 1995-06-14
JPH083064A (ja) 1996-01-09
BR9502797A (pt) 1996-03-12
SE509295C2 (sv) 1999-01-11
RO115124B1 (ro) 1999-11-30
FI952932A (fi) 1995-12-17
GB2290294B (en) 1999-03-17
PE34496A1 (es) 1996-10-01
SE9502168L (sv) 1995-12-17
PT101723B (pt) 1997-02-28
AT408611B (de) 2002-01-25
CA2151564A1 (en) 1995-12-17
GB9512105D0 (en) 1995-08-09
DE19521753B4 (de) 2009-07-23
KR960000923A (ko) 1996-01-25
CO4410204A1 (es) 1997-01-09
YU39795A (sh) 1998-05-15
US5650486A (en) 1997-07-22
SI9500199A (en) 1996-02-29
SE9502168D0 (sv) 1995-06-14
PL183284B1 (pl) 2002-06-28
NL1004643C2 (nl) 1997-02-12
DK67695A (da) 1995-12-17
CN1116629A (zh) 1996-02-14
CZ154395A3 (en) 1996-02-14
GR1002494B (el) 1996-12-12
US5747642A (en) 1998-05-05
PT101723A (pt) 1995-12-29

Similar Documents

Publication Publication Date Title
NL1004643A1 (nl) Werkwijze voor het bereiden van kristallen van AspB28-menselijk insuline en protamine en deze kristallen bevattende farmaceutische formuleringen.
NO20003051D0 (no) Metode for administrering av AspB28-humant insulin
DE122009000064I1 (de) Pharmazeutische Zubereitung enthaltend Pioglitazone und Glimepiride zur Verwendung in der Behandlungvon Diabetes.
DE69832298D1 (de) Gerät zur kontrollierten abgabe von pharmazeutischen und medizinischen produkten
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
PL342162A1 (en) Galenic form for oral administration of either immediate or prolonged drug release containing an absorption enhancing agent and application of such absorption enhancing agent
DE60043305D1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
HUP0002645A3 (en) Phospholipid containing pharmaceutical composition for treating sleep apnea and apparatus for enabling the administration thereof
IT9020025A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in polvere
NL194577B (nl) Preparaat voor de lang aanhoudende en gecontroleerde afgifte van medicamenteuze stoffen.
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
PL322688A1 (en) Cages for holding pasty and liquid preparations with active substance
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0104803A3 (en) Process and system for the administration of medicine through the skin
IL115073A0 (en) 5-substituted pyridine-and hexahydroquinoline-3-carboxylic acid derivatives method for their preparation pharmaceutical compositions containing them and their use
HUP0100853A3 (en) Nitrate salt of anti-ulcer medicine and pharmaceutical compositions containing the same compounds
HUP0003260A3 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
ZA9711129B (en) New analogues of camptothecin their medical application and the pharmaceutical substances that contain them
DE69827417D1 (de) Tizoxanide und/oder Nitazoxanide enthaltende pharmazeutische Zubereitungen
DK415388D0 (da) Farmaceutiske praeparater indeholdende pyrimidinderivater og fremgangsmaade til fremstilling deraf
HUP0003634A3 (en) Use of thiazolidinedione and sulphonylurea derivatives for the preparation of pharmaceutical compositions treating diabetes
ID24195A (id) Sistim terapetik transderual (tts) untuk menghantarkan bahan aktif melelui kulit ke tubuh dan metode untuk penerapan pada kulit
NO953003D0 (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
PD2A A request for search or an international type search has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20150614